Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
4.770
-0.110 (-2.25%)
At close: May 13, 2026, 4:00 PM EDT
4.740
-0.030 (-0.63%)
Pre-market: May 14, 2026, 4:00 AM EDT

Intensity Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
10.2511.922.598.561.314.54
Short-Term Investments
---6.22--
Cash & Short-Term Investments
10.2511.922.5914.781.314.54
Cash Growth
1002.80%360.27%-82.47%1026.22%-71.10%-51.28%
Other Current Assets
0.660.790.770.690.140.19
Total Current Assets
10.9112.713.3615.461.454.73
Net Property, Plant & Equipment
0.090.10.120.150.140.32
Other Long-Term Assets
1.31.31.31.680.170.17
Total Assets
12.2914.14.7817.31.765.22
Accounts Payable
0.640.581.223.050.60.17
Accrued Expenses
1.571.530.510.891.721.35
Current Portion of Leases
0.030.030.030.020.140.18
Other Current Liabilities
----4.352.02
Total Current Liabilities
2.242.151.763.966.823.72
Long-Term Leases
0.070.080.110.14-0.14
Other Long-Term Liabilities
---0.040.040.04
Total Long-Term Liabilities
0.070.080.110.170.040.18
Total Liabilities
2.312.231.874.136.863.9
Preferred Stock
-----0
Common Stock
---0-0
Additional Paid-in Capital
90.890.2769.763.6823.5622.39
Retained Earnings
-80.82-78.39-66.78-50.52-38.65-31.07
Total Common Shareholders' Equity
9.9811.882.9213.16-15.1-8.68
Minority Interest
----1010
Shareholders' Equity
9.9811.882.9213.16-5.11.32
Total Liabilities & Equity
12.2914.14.7817.31.765.22
Total Debt
0.10.110.140.160.140.33
Net Cash (Debt)
10.1411.812.4514.621.174.21
Net Cash Growth
-14.12%381.69%-83.23%1150.47%-72.25%-52.22%
Net Cash Per Share
5.538.714.4142.418.5730.89
Book Value
9.9811.882.9213.16-15.1-8.68
Book Value Per Share
5.448.765.2538.19-110.69-63.66
Tangible Book Value
9.9811.882.9213.16-15.1-8.68
Tangible Book Value Per Share
5.448.765.2538.19-110.69-63.66
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q